STOCK TITAN

Nanovibronix Inc - NAOV STOCK NEWS

Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.

Overview

NanoVibronix Inc is a medical device company that harnesses proprietary low intensity acoustic technology to deliver noninvasive biological response-activating devices. The company is dedicated to transforming therapy through innovative ultrasound applications that enable pain management, wound healing, and biofilm prevention. Operating from its base in Elmsford, NY, with a subsidiary in Nesher, Israel, NanoVibronix strategically positions itself within the broader medical device industry, emphasizing safe and cost-effective treatments that can be administered in home care settings.

Technology and Innovation

At the core of NanoVibronix’s approach is its patented low intensity ultrasound technology. This technology is engineered into miniature transducers capable of transmitting low-frequency acoustic waves through flexible material surfaces. These transducers are integral to the company’s product offerings, as they facilitate the activation of biological responses that promote tissue repair and regeneration. The science behind these devices leverages precise ultrasound parameters to mitigate pain, accelerate wound healing, and prevent the problematic formation of biofilms on urinary catheters. By emphasizing a noninvasive methodology, NanoVibronix is able to provide therapeutic solutions while reducing the risk of adverse side effects, thus reinforcing the safety and reliability of its products.

Product Portfolio and Applications

NanoVibronix has developed a diversified product line that addresses several therapeutic needs. The company markets products designed for home use, which not only offer convenience but also cater to patients seeking alternatives to clinical interventions. Its primary products include device systems such as UroShield, PainShield, and WoundShield. Each product utilizes a small, disposable transducer to emit controlled ultrasound acoustic waves. For instance:

  • UroShield: Focused on combating biofilm formation on urinary catheters, it plays a significant role in reducing the risk of urinary tract infections.
  • PainShield: Designed to target musculoskeletal discomfort, it provides a noninvasive method for pain relief.
  • WoundShield: Aimed at accelerating wound healing, this product supports the regeneration of tissue in a manner that could be administered outside traditional clinical settings.

The simplicity of administration in a home setting enables patients to benefit from therapy without requiring constant medical supervision. This user-friendly approach underlines the company’s commitment to accessible healthcare while maintaining the rigor associated with medical device safety and efficacy.

Market Position and Business Model

NanoVibronix occupies an important niche within the medical device landscape by focusing on low cost, noninvasive therapeutic ultrasound applications. The company generates revenue through the direct sale of its specialized products as well as via strategic distribution agreements. This dual-channel distribution model ensures both market reach and scalability, allowing the company to cater to a wide spectrum of patients from individual users to clinical settings. NanoVibronix consistently seeks to address vital healthcare challenges by offering technologies that mitigate the risks associated with catheter-related infections and provide alternatives to traditional pain management and wound care approaches.

Competitive Differentiation

In a competitive marketplace crowded with varied therapeutic devices, NanoVibronix distinguishes itself through its targeted focus on low intensity acoustic applications. Its proprietary technology not only underpins a unique therapeutic approach but also affords flexibility in treating a range of conditions. By emphasizing noninvasive treatments and the convenience of home administration, NanoVibronix creates a clear value proposition. The company’s robust process of obtaining regulatory clearances for its products further exemplifies its commitment to safety and efficacy, enhancing its reputation among healthcare professionals and patients alike.

Scientific and Clinical Foundations

Underpinning NanoVibronix’s products is a foundation of clinical research and engineering excellence. The controlled use of low intensity ultrasound has been shown in various studies to stimulate biological processes that facilitate tissue repair. The company’s approach tailors these scientific principles into commercially viable, user-friendly devices designed for specific therapeutic outcomes. By focusing on evidence-based clinical practices, NanoVibronix not only upholds high standards of medical efficacy but also contributes meaningfully to the body of knowledge in noninvasive therapeutic technologies.

Regulatory and Safety Considerations

Safety and regulatory compliance are intrinsic to NanoVibronix’s operations. The company ensures that its devices meet stringent regulatory standards, as demonstrated by the FDA clearance achieved by certain products in its portfolio. This regulatory endorsement affirms the quality and reliability of its technology and positions NanoVibronix as a trusted entity within the medical device industry. With a focus on minimizing risks associated with device-based therapies, the company develops products that adhere to established clinical practices while continually monitoring advancements in technology and safety protocols.

Conclusion

In summary, NanoVibronix Inc embodies a confluence of innovative technology and practical medical application. Its pioneering use of low intensity ultrasound serves not merely as a technical achievement but as a transformative approach in addressing everyday healthcare challenges. Through its diversified product offerings and a commitment to noninvasive, home-based therapies, NanoVibronix provides solutions that are both effective and accessible. The company's clear emphasis on clinical efficacy, regulatory safety, and a strategic market position illustrates why it remains a distinctive name in the realm of medical device innovation.

Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has renewed and expanded its exclusive three-year distribution agreement with Dukehill Healthcare for its UroShield device across all Australian States. The agreement, previously focused on Queensland and New South Wales, now extends to South Australia and Victoria following increased healthcare facility inquiries.

The expansion comes after the publication of an independent study highlighting UroShield's effectiveness in reducing catheter-associated complications and improving patient outcomes. Dukehill will showcase UroShield at the 33rd National Conference on Incontinence in Hobart in May 2025, where clinicians will discuss the study findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) announced the publication of an independent health service study of its UroShield® device in The Australian and New Zealand Continence Journal. The study demonstrated significant improvements in patient care and cost reduction for those with indwelling urinary catheters.

Key findings include:

  • 86% reduction in UTI incidence
  • 70% reduction in catheter blockages
  • 82.8% decrease in bladder irrigations
  • 52.3% reduction in catheter changes
  • 63.5% reduction in resource costs over 5 months

The study, conducted by a New Zealand District Nursing Service, highlighted UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and improving patient comfort while reducing healthcare provider costs through decreased nursing time and fewer interventions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
819.51%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has announced a 1-for-11 reverse stock split effective March 13, 2025. The stock will begin trading on a split-adjusted basis on March 14, 2025, maintaining its NASDAQ symbol NAOV.

The reverse split, approved by stockholders on February 24, 2025, will reduce outstanding shares from 8,716,327 to approximately 792,394. The conversion will be automatic, with fractional shares rounded up to the nearest whole number. The split will not alter stockholders' percentage ownership in the company.

Proportional adjustments will be made to equity awards, warrants, and other convertible securities. The company's common stock will trade under a new CUSIP number: 63008J702.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.15%
Tags
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has completed the acquisition of ENvue Medical Holdings Corp., a private company specializing in enteral feeding solutions. The strategic acquisition aims to strengthen the combined company's market position in enteral feeding technology and therapeutic medical devices.

The merger is expected to leverage ENvue's proprietary technology alongside NanoVibronix's existing portfolio, creating a broader commercial platform with enhanced distribution and operational efficiencies. The combined entity will focus on addressing patient safety challenges in enteral feeding while expanding market reach in the medical device sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has completed the design phase for its next-generation PainShield® and UroShield® devices through a third-party contractor in December 2024. The new prototypes aim to reduce assembly costs and improve user experience.

Key design updates include: an additional therapy mode for enhanced efficacy, future-proofed componentry ensuring availability throughout manufacturing, streamlined software for better performance, and improved user interface with USB-C connectors. For the UroShield® model, a single lead design has been implemented to simplify device setup.

The company is now advancing to the validation and testing phase based on received feedback and protocols. These developments represent a significant milestone in NanoVibronix's strategy to achieve broader healthcare community adoption and increase unit sales of their Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.3%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has successfully completed the pilot phase of a Randomized Control Trial study for UroShield® at the University of Michigan. The study, primarily conducted with nursing home residents, focused on evaluating UroShield's impact on reducing urinary tract infections, catheter blockages, and pain associated with long-term urinary catheter use.

The completed pilot phase served as a validation step before advancing to the full study, which is expected to commence in 2025. The research team has achieved their initial goals, including refining recruitment strategies and developing data collection tools. This research complements previous studies and product launches in the UK, Australia, and New Zealand, as well as the recent introduction to the European market. The company is simultaneously preparing for a U.S. launch, pending FDA 510K clearance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.47%
Tags
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has renewed its exclusive distribution agreement with Ultra Pain Products (UPPI) for PainShield distribution for another five years. The agreement includes a minimum purchase commitment of $12 million. The renewal follows UPPI's significant growth over the past four years and its evolution in the non-opioid pain management and injury recovery industry.

The collaboration aims to strengthen both companies' market presence, with UPPI continuing to distribute NanoVibronix's proprietary PainShield as part of its expanding portfolio of technologies. The partnership focuses on providing innovative non-opioid treatment options while prioritizing safety, efficacy, and accessibility in the U.S. market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
none
-
News
Rhea-AI Summary

NanoVibronix, a medical device company, provided a business update highlighting recent developments. CEO Brian Murphy emphasized progress in expanding distribution, raising commercial awareness, and pursuing reimbursements. The company's products, including UroShield®, PainShield®, and WoundShield®, continue to show high patient satisfaction.

The company signed a letter of intent with Kriel Technology Group to explore UroShield distribution in South Africa, with a market evaluation planned for early next year. Independent research presented at major medical conferences demonstrated UroShield's effectiveness in reducing catheter-associated urinary tract infections (CAUTIs).

Reimbursement efforts include a successful application for UroShield actuators on NHS Prescription Services' Drug Tariff and ongoing submissions for full reimbursement in the UK and Germany. The company remains optimistic about expanding its market presence and increasing product awareness globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH, a German pharmaceutical company specializing in urology products. The agreement aims to distribute UroShield throughout Europe. UroShield is an ultrasound-based device designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, potentially reducing catheter-associated urinary tract infections (CAUTI) and associated pain.

Brian Murphy, CEO of NanoVibronix, expressed enthusiasm about partnering with APOGEPHA, citing their leadership in urology and large sales and marketing team as key factors for accelerating UroShield sales in Germany. Dr. Dirk Pamperin, Chairman of APOGEPHA's Management Board, stated their commitment to offering high-quality urological products and their confidence in UroShield's ability to support patients with long-term catheters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
Rhea-AI Summary

NanoVibronix, Inc. (NASDAQ: NAOV) has signed a letter of intent with Medici Medical , a leading distributor of medical products in Israel, to explore distribution opportunities for its UroShield device in the Israeli healthcare market. This potential partnership aligns with NanoVibronix's strategy to expand distribution and accelerate market adoption of UroShield through established channels.

Brian Murphy, CEO of NanoVibronix, emphasized the importance of partnering with leading distributors to drive market adoption. Medici's CEO, Nufar Cohen, expressed interest in UroShield's reported benefits and plans to evaluate it further through market research. Medici specializes in importing, marketing, and distributing disposable medical devices and has established partnerships with international pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none

FAQ

What is the current stock price of Nanovibronix (NAOV)?

The current stock price of Nanovibronix (NAOV) is $2.36 as of April 4, 2025.

What is the market cap of Nanovibronix (NAOV)?

The market cap of Nanovibronix (NAOV) is approximately 2.0M.

What is NanoVibronix Inc focused on?

NanoVibronix Inc is focused on developing noninvasive medical devices that utilize low intensity ultrasound technology for pain management, wound healing, and biofilm prevention.

How does the company generate revenue?

NanoVibronix generates revenue through the direct sale of its device systems to patients and through agreements with distributors, ensuring broad market coverage.

What are the primary products offered by NanoVibronix?

The company offers a suite of products including devices like UroShield, PainShield, and WoundShield, all of which are designed to deliver therapeutic low-frequency ultrasound treatments.

What is unique about NanoVibronix's technology?

Its proprietary technology is based on low intensity acoustic waves transmitted by miniature transducers, which uniquely enable therapeutic applications in a noninvasive and home-based setting.

How do NanoVibronix devices benefit patients?

The devices promote tissue repair, reduce pain, accelerate wound healing, and prevent biofilm formation on catheters, providing a simple and user-friendly solution for home healthcare.

What makes NanoVibronix's approach different from other medical devices?

NanoVibronix distinguishes itself by focusing on low cost, noninvasive ultrasound-based treatments that can be easily administered outside of traditional clinical environments.

Are NanoVibronix products regulated for safety?

Yes, the company ensures that its products meet stringent regulatory standards, with approvals such as FDA clearance affirming the safety and effectiveness of its technology.

How does NanoVibronix contribute to biofilm prevention?

Through its innovative UroShield product, the company uses low intensity ultrasound to disrupt biofilm formation on urinary catheters, thereby reducing the risk of urinary tract infections.
Nanovibronix Inc

Nasdaq:NAOV

NAOV Rankings

NAOV Stock Data

2.02M
751.76k
0.95%
2%
3.07%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
TYLER